FGFR2 and cholangiocarcinoma: For cholangiocarcinomas in particular, molecular techniques can evaluate the possibility to target actionable genomic alterations with approved agents such as include ivosidenib for tumors harboring IDH1 mutations, and infigratinib and pemigatinib for those with FGFR2 fusions (18).